505 related articles for article (PubMed ID: 18197170)
1. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
[TBL] [Abstract][Full Text] [Related]
2. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
van Gils MJ; Sanders RW
Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
[TBL] [Abstract][Full Text] [Related]
4. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
5. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
6. Rational antibody-based HIV-1 vaccine design: current approaches and future directions.
Walker LM; Burton DR
Curr Opin Immunol; 2010 Jun; 22(3):358-66. PubMed ID: 20299194
[TBL] [Abstract][Full Text] [Related]
7. GP120: target for neutralizing HIV-1 antibodies.
Pantophlet R; Burton DR
Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265
[TBL] [Abstract][Full Text] [Related]
8. Toward an antibody-based HIV-1 vaccine.
Hoxie JA
Annu Rev Med; 2010; 61():135-52. PubMed ID: 19824826
[TBL] [Abstract][Full Text] [Related]
9. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
12. Challenges for structure-based HIV vaccine design.
Schief WR; Ban YE; Stamatatos L
Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
[TBL] [Abstract][Full Text] [Related]
13. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
[TBL] [Abstract][Full Text] [Related]
14. Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B-cell responses after boosting.
Sundling C; Martinez P; Soldemo M; Spångberg M; Bengtsson KL; Stertman L; Forsell MN; Karlsson Hedestam GB
J Infect Dis; 2013 Feb; 207(3):426-31. PubMed ID: 23162135
[TBL] [Abstract][Full Text] [Related]
15. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
16. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
17. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
18. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
19. Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Ye L; Sun Y; Lin J; Bu Z; Wu Q; Jiang S; Steinhauer DA; Compans RW; Yang C
Virology; 2006 Aug; 352(1):74-85. PubMed ID: 16725170
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.
Burton DR; Poignard P; Stanfield RL; Wilson IA
Science; 2012 Jul; 337(6091):183-6. PubMed ID: 22798606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
